|Day's Range||15.00 - 15.00|
UnitedHealth Group Chief Scientific Officer Ken Ehlert joins Yahoo Finance’s Anjalee Khemlani and Seana Smith to discuss the new testing kit that will enable patients to test themselves for the virus at home.
Chief Financial Analyst at Bankrate.com Greg McBride joins Yahoo Finance’s Zack Guzman, Emily McCormick and Clearnomics Founder & CEO James Liu on YFi PM to discuss the response to the coronavirus as cases surpass 1,700 in the United States.
Cases of coronavirus surpassed 100,000 worldwide, with New York cases tripling in just 48 hours. Yahoo Finance’s Anjalee Khemlani breaks down the details with Seana Smith.
Quest Diagnostics announced it will begin screening for the coronavirus. Yahoo Finance’s Anjalee Khemlani joins Seana Smith on The Ticker to discuss.
Amgen (NASDAQ:AMGN) today announced positive results from the EvolocumaB Effect on LDL-C LowerIng in SubJEcts with Human Immunodeficiency ViRus and INcreased Cardiovascular RisK (BEIJERINCK) study evaluating the efficacy and safety of Repatha® (evolocumab) in patients who are human immunodeficiency virus-positive (HIV+) and have high low-density lipoprotein cholesterol (LDL-C) despite stable background lipid-lowering therapy.1 The study demonstrated that treatment with Repatha significantly reduced LDL-C. The results were featured as an oral presentation during the virtual American College of Cardiology's 69th Annual Scientific Session from March 28-30, 2020 with publication in the Journal of the American College of Cardiology (JACC) on March 30, 2020.
As the government prepares to bail out industries amid the Covid-19 pandemic, stock buybacks are falling out of favor. One sector that does a lot of repurchases? The biopharma industry.
With the COVID-19 crisis sending the U.S. economy in a recession, we're looking at what companies managed to thrive during the last recession for guidance.
Amgen stock is facing concerns that biosimilars could chip away at some of its biggest moneymakers. Is it time to buy shares of the biotech company?
Biotech company Amgen is committing $12.5 million to support relief efforts to address needs in communities impacted by the COVID-19 pandemic.
Amgen (NASDAQ:AMGN) and the Amgen Foundation today announced an initial commitment of up to $12.5 million to support U.S. and global relief efforts to address critical needs in communities impacted by the COVID-19 pandemic. The funds will be used to support emergency response efforts in Amgen's U.S. and international communities, patient-focused organizations that are mounting their own response efforts, and international relief efforts by Direct Relief and International Medical Corps. The Amgen Foundation will also match donations made by Amgen staff around the globe who wish to contribute their own funds to the relief efforts.
Technical analysis offers unique insights into market trends, especially in times of chaos. Why three practitioners see support for the S&P 500 around 2300. What the charts say about oil, emerging markets, health care, Walmart.
The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We'll apply a basic P/E...
(Bloomberg Opinion) -- The $8.3 billion spending bill that President Donald Trump signed last week to address the coronavirus crisis contains a provision that could be costly: When a vaccine for the virus becomes available, the law says, the government can spend no more than a “fair and reasonable” price for it. But it does not require the drugmaker to accept such a payment.The law includes a pricing mechanism, but it relies in part on comparisons with other vaccine prices, and these vary widely: Medicare reimburses about $56 for Sanofi’s influenza vaccine, $500 per course for Merck’s human papilloma vaccine, and $5,000 per injection for Amgen’s melanoma vaccine.Inevitably, then, when an effective, desperately needed vaccine is ready, we can expect a pricing standoff. To avoid this, the government should buy vaccines now, even before they’re invented. This would guarantee a good price for the government, and it would benefit drugmakers by ensuring a market for their products. Our government routinely procures items that are not yet designed and built. Engines for fighter jets are purchased when they are sketches on paper, as are federal office buildings. Vaccines needed for the developing world are sometimes pre-purchased through advanced market commitments. In all cases the contracts specify minimum requirements for the ultimate product.It’s easy to imagine the profile for a Covid-19 vaccine. First, it would need to be effective enough to curtail spread. Early vaccines rarely work on everyone, but even modest effectiveness would provide large benefits to public health. And while the immunity conferred by a vaccine can wane, what’s needed most immediately is near-term protection. Expected side effects should be rare, and monitoring for severe ones should be required.We would also need this vaccine to be produced at population scale within a year. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, has said this is a scientifically achievable timeline. Production, distribution, outreach and delivery would all be part of a staged contract.Using these specifications, the government would solicit bids, and each responding vaccine developer would propose the price it would charge for developing and delivering a vaccine, either alone or with partners. Because any one vaccine is unlikely to be perfect or perfectly supplied, we should select three or more winners.The alternative is to wait for the U.S. pharmaceutical industry to develop a vaccine on its own, relying on existing market mechanisms to protect against the usual risks of drug development. The first of these is the risk inherent in investing money and time on a drug that may turn out not to be effective. Vaccine science mitigates this threat. The Coalition for Epidemic Preparedness Innovations has already developed eight promising vaccine candidates against Covid-19. And 25 companies are ready to work on a vaccine.The second uncertainty is whether there will turn out to be a market for the products that drugmakers create. The government contract approach we propose mitigates that possibility. Both of us know from experience the problems that arise when unaffordability keeps an essential medical treatment out of reach. We helped develop the subscription model that Louisiana and the state of Washington use to finance expensive drugs to treat hepatitis C: The states pay a flat fee in return for as many courses of treatment as they need.The federal government could follow a similar “Netflix financing” model to pay a single price to vaccinate the population against the coronavirus.We don’t know how much such a contract will cost. But asking for bids will lead companies to put forward their best prices. The winners will make money (including by selling their vaccines overseas) while showing off their scientific prowess and the important role they play in public health. And the federal government can make sure everyone in the U.S. is protected against Covid-19.To contact the authors of this story: Peter B. Bach at email@example.comMark Trusheim at firstname.lastname@example.orgTo contact the editor responsible for this story: Mary Duenwald at email@example.comThis column does not necessarily reflect the opinion of Bloomberg LP and its owners.Peter B. Bach, a physician, directs the Drug Pricing Lab at Memorial Sloan Kettering Cancer Center in New York. Mark Trusheim is a visiting scientist at the MIT Sloan School of Management. For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
As stocks sank, Barron’s Roundtable panelists shopped. Why they like Disney, Merck, and Charles Schwab, even if a recession is coming.
Coronavirus is probably the 1 concern in investors’ minds right now. It should be. On February 27th we publish an article with the title "Recession is Imminent: We Need A Travel Ban NOW". We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
Amgen (AMGN) boasts a strong biosimilars portfolio, which can drive long-term growth. Amgen is also progressing with its pipeline while regularly pursuing business development deals.